Biotechnology Stocks Trader's Buzzers : Achillion Pharmaceuticals, (ACHN), Advaxis, Inc. (ADXS) , Alexion Pharmaceuticals, (ALXN) , Amgen, (AMGN) , Albany Molecular Research, (AMRI)

Biotechnology is the use of biological processes, organisms, or systems to manufacture products intended to improve the quality of human life. The earliest biotechnologists were farmers who developed improved species of plants and animals by cross pollenization or cross breeding. In recent years, biotechnology has expanded in sophistication, scope, and applicability.

The science of biotechnology can be broken down into subdisciplines called red, white, green, and blue. Red biotechnology involves medical processes such as getting organisms to produce new drugs, or using stem cells to regenerate damaged human tissues and perhaps re-grow entire organs. White (also called gray) biotechnology involves industrial processes such as the production of new chemicals or the development of new fuels for vehicles. Green biotechnology applies to agriculture and involves such processes as the development of pest-resistant grains or the accelerated evolution of disease-resistant animals. Blue biotechnology, rarely mentioned, encompasses processes in marine and aquatic environments, such as controlling the proliferation of noxious water-borne organisms. {1}

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed declined -0.33% to $12.25,recently declared positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422.

"We believe that achievement of 100 percent SVR4 in six weeks in the ACH-3102 proxy study, combined with the high potency and safety demonstrated by ACH-3422, highlights the ability of our exceptional, fully owned portfolio to excel in the HCV market," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We look forward to initiating in 2015 short duration, pan-genotypic Phase 2 therapeutic trials to evaluate the doublet of ACH-3102 and ACH-3422, with the ultimate goal of improving patient care and access to treatment."

Advaxis, Inc. (NASDAQ:ADXS) closed lower -8.87% to $8.01, a biotechnology organization developing cancer immunotherapies, declared that its Lm-LLO immunotherapy technology was highlighted on FOX News Channel's Sunday Housecall. The segment, which aired on December 28, 2014, featured Drs. Marc Siegel and David Samadi discussing Advaxis's cancer immunotherapy as a potential treatment for a range of cancer indications, including breast, prostate, osteosarcoma, and head and neck, due to its potential to trigger the immune system to directly attack cancer cells.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) closed gained 0.05% to $185.03, recently declared completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP). HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.1-5

Amgen, Inc. (NASDAQ:AMGN) closed declined -0.83% to $159.29, Amgen, Inc. and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, recently declared a contract in which Amgen has become a LabCentral platinum sponsor. As part of the sponsorship contract, Amgen can nominate up to two promising life-sciences and biotech startup companies per year to take up residence in LabCentral's Kendall Square facilities.

Albany Molecular Research, Inc. (NASDAQ:AMRI) closed increased 2.58% to $16.28, Levi & Korsinsky declares that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Albany Molecular Research Inc. (“Albany Molecular” or the “Company”) (AMRI) securities between August 5, 2014 and November 5, 2014.

 TAGs:

Achillion Pharmaceuticals, NASDAQ:ACHN, Advaxis, NASDAQ:ADXS , Alexion Pharmaceuticals, NASDAQ:ALXN , Amgen, NASDAQ:AMGN , Albany Molecular Research, NASDAQ:AMRI, ACHN, ADXS, ALXN, AMGN,AMRI

Source {1}: techtarget.com